Stockreport

Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR® in Japanese Adults with Generalized Anxiety Disorder (GAD) [Yahoo! Finance]

Viatris Inc.  (VTRS) 
PDF EFFEXOR ® was generally well tolerated, consistent with its known safety profile Pharmaceuticals and Medical Devices Agency (PMDA) submission targeted for 2025 PITT [Read more]